Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + bevacizumab + pegargiminase
- Development stage
- Phase 2
- Lead developer
- Polaris Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intramuscular
01
Overview
atezolizumab + bevacizumab + pegargiminase is a combination therapy being evaluated for the treatment of locally advanced or metastatic hepatocellular carcinoma (HCC). The regimen consists of pegargiminase (ADI-PEG 20), a pegylated recombinant arginine deiminase that depletes systemic arginine to starve argininosuccinate synthetase 1 (ASS1)-deficient tumor cells; atezolizumab, a monoclonal antibody targeting programmed cell death 1 ligand 1 (PD-L1) to restore anti-tumor T-cell activity; and bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A) to inhibit tumor angiogenesis. This triplet combination is being investigated in clinical trials, notably at the M.D. Anderson Cancer Center, to determine if the metabolic stress induced by arginine depletion can synergize with immune checkpoint blockade and anti-angiogenic therapy to improve clinical outcomes in patients with advanced liver cancer.
- Other names
- ADI-PEG 20 + atezolizumab + bevacizumab
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on atezolizumab + bevacizumab + pegargiminase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + bevacizumab + pegargiminase.